| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
3-Epioleanolic acid is observed to mediate its effect through the cholinergic receptor (AChR). It and oleanonic acid possess varying degrees of agonist activity on uterine smooth muscle. It also has antioxidant and antimicrobial effects.
|
|---|---|
| ln Vitro |
In cell-free systems, the activity of 3-Epioleanolic acid is assessed by its ability to bind to the cholinergic receptor. Receptor binding assays are used to determine its affinity for AChR. Its agonist activity on uterine smooth muscle can be measured in tissue bath assays. 3-Epioleanolic acid exhibits anti-inflammatory activity in vitro. It may also have antioxidant and antimicrobial effects. Its effects on cells are likely mediated through its interaction with the cholinergic receptor and other pathways.
|
| ln Vivo |
3-Epioleanolic acid has been shown to possess varying degrees of agonist activity on uterine smooth muscle. This suggests it may have effects on smooth muscle contraction in vivo. Its anti-inflammatory activity has also been observed.
|
| Enzyme Assay |
The activity of 3-Epioleanolic acid on the cholinergic receptor can be measured in cell-free receptor binding assays. The compound's ability to displace a labeled ligand from the receptor is used to determine its binding affinity. Its agonistic activity is confirmed in functional assays.
|
| Cell Assay |
Cells are treated with 3-Epioleanolic acid, and its effects on cholinergic receptor signaling are measured. This may involve measuring changes in intracellular calcium levels or other downstream signaling events. Its anti-inflammatory effects can be assessed by measuring cytokine production.
|
| Animal Protocol |
In vivo studies for 3-Epioleanolic acid may involve assessing its effects on uterine smooth muscle contraction in animal models. Its anti-inflammatory activity can be evaluated in standard models of inflammation, such as carrageenan-induced paw edema.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 3-Epioleanolic acid are not well-documented. As a triterpenoid, its oral bioavailability may be limited. Its metabolism and excretion are not well-characterized. Further studies are needed to determine its ADME profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for 3-Epioleanolic acid is limited. It is generally considered safe for research use. Its safety profile requires further investigation, especially if it is to be developed as a therapeutic agent.
|
| References | |
| Additional Infomation |
3-Epiooleanolic acid is a triterpenoid compound and a metabolite. It has been reported to be found in Scutellaria baicalensis, Sage, and other organisms with relevant data.
3-Epioleanolic acid is a natural product with potential therapeutic applications. It is a valuable compound for pharmacological and biochemical research. It is not an approved drug and is for research use only. |
| Molecular Formula |
C30H48O3
|
|---|---|
| Molecular Weight |
456.7003
|
| Exact Mass |
456.36
|
| CAS # |
25499-90-5
|
| PubChem CID |
11869658
|
| Appearance |
White to off-white solid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
553.5±50.0 °C at 760 mmHg
|
| Melting Point |
297-299 °C
|
| Flash Point |
302.6±26.6 °C
|
| Vapour Pressure |
0.0±3.4 mmHg at 25°C
|
| Index of Refraction |
1.557
|
| LogP |
9.06
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
33
|
| Complexity |
885
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
O([H])[C@]1([H])C([H])([H])C([H])([H])[C@@]2(C([H])([H])[H])[C@]([H])(C1(C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])[C@@]1(C([H])([H])[H])[C@]3(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]4(C(=O)O[H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[C@@]4([H])C3=C([H])C([H])([H])[C@@]12[H]
|
| InChi Key |
MIJYXULNPSFWEK-KDQGZELNSA-N
|
| InChi Code |
InChI=1S/C30H48O3/c1-25(2)14-16-30(24(32)33)17-15-28(6)19(20(30)18-25)8-9-22-27(5)12-11-23(31)26(3,4)21(27)10-13-29(22,28)7/h8,20-23,31H,9-18H2,1-7H3,(H,32,33)/t20-,21-,22+,23+,27-,28+,29+,30-/m0/s1
|
| Chemical Name |
(4aS,6aR,6aS,6bR,8aR,10R,12aR,14bS)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~218.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.47 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1896 mL | 10.9481 mL | 21.8962 mL | |
| 5 mM | 0.4379 mL | 2.1896 mL | 4.3792 mL | |
| 10 mM | 0.2190 mL | 1.0948 mL | 2.1896 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
